Stockscreener 앱 받기
21.97
2.53%
-0.57
시장 영업 전:
22.00
0.03
+0.14%
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
Acadia Pharmaceuticals at The Citizens Life Sciences Conference: Strategic Growth and Innovations - Investing.com India
ACADIA Pharmaceuticals Showcases $1B+ Net Sales, $800M Cash, and Key Alzheimer’s Readout Ahead - Yahoo Finance
ACADIA Pharmaceuticals to exhibit at ACMG event in Baltimore - Traders Union
ACAD plans re-examination after CHMP rejects Rett syndrome drug in EU (revised) - MSN
Neo Ivy Capital Management Buys Shares of 62,568 ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals (ACAD) Valuation After CHMP Setback On Trofinetide For Rett Syndrome - Sahm
Why ACADIA Pharmaceuticals (ACAD) Is Down 9.1% After EU Setback on Trofinetide Approval Effort - Sahm
Acadia Pharmaceuticals appoints Jonathan M. Poole to board of directors By Investing.com - Investing.com Canada
Acadia Pharmaceuticals appoints Jonathan M. Poole to board of directors - Investing.com Nigeria
Acadia Pharmaceuticals Appoints Jonathan Poole to Board, Audit Committee - TipRanks
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised) - Finviz
ACADIA Pharmaceuticals Inc. $ACAD Stock Position Raised by Fisher Asset Management LLC - MarketBeat
Acadia Faces EU Setback On Trofinetide As Valuation Signals Diverge - Yahoo Finance
Is It Time To Revisit ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness? - Yahoo Finance
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU - The Globe and Mail
JP Morgan Raises Price Target for ACADIA Pharmaceuticals (ACAD) to $34 | ACAD Stock News - GuruFocus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
CHMP Setback Puts Acadia Rett Plans And Revenue Outlook In Focus - simplywall.st
ACAD Announces New Review Following CHMP’s Decision Against Rett Syndrome Medication in Europe - Bitget
Rafferty Asset Management LLC Boosts Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors - BioSpace
ACADIA (ACAD) -7.1%: EU Agency Rejects Rett Syndrome Drug - Trefis
Acadia Pharmaceuticals appoints Jonathan M. Poole to its board of directors - marketscreener.com
Acadia Pharmaceuticals Appoints Jonathan M. Poole To Its Board Of Directors - TradingView
ACADIA Stock (-7.1%): EU Regulator Rejects Rett Syndrome Drug Trofinetide - Trefis
Acadia, undaunted by recent EU rejection, seeks CHMP re-examination of Rett syndrome med Daybue - Fierce Pharma
Inside Biotech: Acadia seeks second look from European regulators on trofinetide - Proactive financial news
Acadia Faces EU Setback On Trofinetide As Valuation Gap Widens - simplywall.st
Prolium’s $50M Series A raise; COUR Pharma touts liver drug follow-up - Endpoints News
ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis: Navigating a 38.97% Potential Upside Amid Biotech Challenges - DirectorsTalk Interviews
Acadia receives negative EU opinion for Rett syndrome drug - Investing.com India
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
BofA cuts Acadia Pharmaceuticals stock price target on EU setback By Investing.com - Investing.com Canada
BofA cuts Acadia Pharmaceuticals stock price target on EU setback - Investing.com South Africa
BofA cuts Acadia Pharmaceuticals price target on pipeline review By Investing.com - Investing.com Nigeria
BofA cuts Acadia Pharmaceuticals price target on pipeline review - Investing.com
ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Teases Key Phase 2 Data in 2025 - MarketBeat
ACADIA Pharmaceuticals recently announced that, following a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding its Rett syndrome treatment Trofinetide, the company plans to formall - Bitget
Acadia receives negative EU opinion for Rett syndrome drug By Investing.com - Investing.com UK
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome - marketscreener.com
Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.'s (ACAD) Therapeutic Domains - Bitget
Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.’s (ACAD) Therapeutic Domains - Yahoo Finance
Acadia Pharmaceuticals' Rett Syndrome Medication Less Likely to Receive EU Approval, RBC Says - marketscreener.com
HC Wainwright Brokers Decrease Earnings Estimates for ACAD - MarketBeat
ACADIA Pharmaceuticals Charts Growth Path After Record Year - TipRanks
Erste Asset Management GmbH Lowers Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Acadia Pharmaceuticals (ACAD) Margin Expansion To 36.5% Tests Bearish Earnings Narratives - Sahm
Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker - Seeking Alpha
Vanguard Group Inc. Reduces Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Lawsuit - GuruFocus
ACADIA Pharmaceuticals' Rett Syndrome Drug Faces EMA Setback - marketscreener.com
What is HC Wainwright's Estimate for ACAD Q3 Earnings? - MarketBeat
1.57%
0.40%
자본화:
|
볼륨(24시간):